^
3d
Global Lipidomic Analysis of Lytic KSHV Infection: The lipid chaperone FABP4 is required for maximal infectious virion production. (PubMed, bioRxiv)
Moreover, our intracellular and extracellular viral titers indicate that FABP4 affects maximal infectious virion production. This study highlights the role of FABP4 and its therapeutic potential as a target that facilitates KSHV infection and pathogenesis.
Journal
|
FABP4 (Fatty Acid Binding Protein 4)
3d
Repurposing Product Nkabinde for Hepatitis B Virus Therapy: A Network Pharmacology and Molecular Docking Investigation. (PubMed, Pharmaceuticals (Basel))
Conserved hydrogen bonds, π-cation interactions, and significant hydrophobic packing at ATP-binding clefts and regulatory domains supported these interaction patterns, indicating competitive suppression of host signaling nodes taken over by HBV. Together, these results demonstrate that the components of PN possess strong multitarget binding capabilities across the PI3K/AKT, JAK-STAT, SRC-family kinase, EGFR, and SYK pathways, supporting their potential repurposing as host-directed HBV therapeutics with the ability to impede immune evasion, viral persistence, and HBV-associated oncogenic progression.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • SYK (Spleen tyrosine kinase) • STAT1 (Signal Transducer And Activator Of Transcription 1)
7d
KSHV Genome in Saliva, Whole Blood and Kaposi's Sarcoma Biopsy Specimens in Republic of Congo: Phylogenetic Analysis and an APOBEC3B Mutational Signature. (PubMed, J Med Virol)
KSHV sequences from Congo samples present phylogenetic particularities but remain close to the whole genome sequences found in Sub-Saharan Africa. We were able to observe, using bioinformatics tools, only very few mutations due to APOBEC3B on KSHV genome.
Journal
|
APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B)
11d
SFPQ prevents MDA5-mediated activation of innate immunity and preserves cell viability. (PubMed, Cell Rep)
Moreover, SFPQ depletion in uninfected cells induced IFN response genes, including MDA5 and ZBP1, and impaired cell growth. In summary, SFPQ binds ADAR1 and modulates its editing function, thereby preventing cellular RNAs from activating MDA5-mediated innate immune responses.
Journal
|
IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • ADAR (Adenosine Deaminase RNA Specific) • IFIH1 (Interferon Induced With Helicase C Domain 1)
17d
Nirogacestat in Patients With Kaposi Sarcoma (clinicaltrials.gov)
P2, N=28, Not yet recruiting, AIDS Malignancy Consortium
New P2 trial
|
CD4 (CD4 Molecule)
|
Ogsiveo (nirogacestat)
19d
Non-canonical histone H3.3 and its chaperones HIRA and DAXX participate in the regulation of KSHV latency. (PubMed, bioRxiv)
Moreover, we demonstrated that genetically disrupting the host H3.3 chaperone HIRA pathway by CRISPR/Cas9-mediated knockout impacted the regulation of LANA and maintenance of viral latency that was not altered in DAXX knockout cells. Collectively, these results support a role for HIRA-mediated H3.3 deposition in the regulation of KSHV latency.
Journal
|
DAXX (Death-domain associated protein)
22d
ANTARES: Agnostic Therapy in Rare Solid Tumors (clinicaltrials.gov)
P2, N=28, Recruiting, Instituto do Cancer do Estado de São Paulo | Active, not recruiting --> Recruiting
Enrollment open • IO biomarker • Pan tumor
|
FH (Fumarate Hydratase) • MITF (Melanocyte Inducing Transcription Factor)
|
Opdivo (nivolumab)
25d
KAPKEY: Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma (clinicaltrials.gov)
P2, N=17, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting
Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab)
26d
Oncovirus-Driven Endothelial Plasticity: Endothelial-to-Mesenchymal Transition as a Hijacked Pathway in Oncoviral Cardiovascular Pathogenesis. (PubMed, Rev Med Virol)
This virus-driven EndMT contributes to vascular remodelling, chronic inflammation, aberrant angiogenesis, and the development of oncoviral-associated cardiovascular pathology and vascular tumours. The present review integrates current virological and mechanistic insights into EndMT as a hijacked host process, highlighting its role at the virus-host interface and discussing emerging antiviral and pathway-targeted strategies aimed at limiting oncovirus-mediated endothelial dysfunction.
Review • Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • TGFB1 (Transforming Growth Factor Beta 1)
1m
Host microRNA-31-5p regulates KHDRBS3 expression and modulates viral gene expression during KSHV lytic reactivation. (PubMed, Cell Rep)
We characterize KHDRBS3 as a major host factor that is critical for KSHV lytic replication and uncover its key role in KSHV lytic gene transcription. Our results highlight a pivotal role for the miR-31-5p/KHDRBS3 axis in modulating KSHV reactivation and provide insights into gene-expression regulation of lytic KSHV.
Journal
|
KHDRBS3 (KH RNA Binding Domain Containing, Signal Transduction Associated 3) • MIR31 (MicroRNA 31)
1m
Skin conditions in persons living with HIV during hospital admission in the UK. (PubMed, Skin Health Dis)
Bacterial cellulitis was the most common dermatological condition overall, while oral candidiasis was the most common condition in those with advanced HIV infection. Further work is needed to better characterize the profile of skin disease in PLHIV, including in larger prospective cohorts and outpatient settings.
Journal
|
CD4 (CD4 Molecule)
1m
STARKAP: Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma (clinicaltrials.gov)
P1, N=15, Active, not recruiting, Imperial College London | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Apr 2026 --> Jul 2026
Enrollment closed • Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
Jemperli (dostarlimab-gxly)